Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.06 -0.65%

-$0.02 today

Market cap
$106.78M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.02M

Average 0.04M

Returns on capital

Cellectis S.A. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-89.1%

avg -47.9%

ROIC

-16.7%

avg -26.3%

ROA

-20.8%

avg -21.9%

Analysis

ROIC is currently the strongest return metric at -16.7% versus its period average of -26.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Andre Choulika

Co-Founder, Chief Executive Officer & DirectorUSD 982.87K61——

David J. Sourdive

Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and DirectorUSD 636.27K59——

Philippe Duchateau

Chief Scientific Officer—63——

Arthur Stril

Chief Financial Officer & Chief Business Officer—37——

Jean Charles Epinat

Chief Technological Officer————

Stephan Reynier

Chief Regulatory & Pharmaceutical Compliance Officer—57——

Kyung Nam-Wortman

Executive Vice President & Chief Human Resources Officer—56——

Marie-Bleuenn Terrier

General Counsel & Secretary of the Board of Directors—44——

Pascalyne Wilson

Director of Communications————

Valerie Cros

Principal Financial Officer & Principal Accounting Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+56.1%
-19.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +56.1% over three years. Forward estimates point to Revenue at -19.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Cellectis S.A. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CLLS's management, answered from reported figures.

Who manages CLLS?

Cellectis S.A. (CLLS) lists 10 active executives. The top listed executive is Andre Choulika, Co-Founder, Chief Executive Officer & Director.